Format

Send to

Choose Destination
Actas Dermosifiliogr. 2016 Nov;107(9):740-750. doi: 10.1016/j.ad.2016.04.020. Epub 2016 Jul 18.

Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part II: Photodynamic Therapy, Vismodegib, Cetuximab, Intralesional Methotrexate, and Radiotherapy.

[Article in English, Spanish]

Author information

1
Unidad de Dermatología, Hospital de Barbastro, Barbastro, Huesca, España; Instituto Aragonés de Ciencias de la Salud, Zaragoza, España. Electronic address: tamgracaz@gmail.com.
2
Departamento de Biología, Facultad de Ciencias, Universidad Autónoma de Madrid, Madrid, España.

Abstract

A wide range of treatments is now available for nonmelanoma skin cancer, including 5-fluorouracil, ingenol mebutate, imiquimod, diclofenac, photodynamic therapy, methotrexate, cetuximab, vismodegib, and radiotherapy. All are associated with high clinical and histologic response rates. However, some tumors do not respond due to resistance, which may be primary or acquired. Study of the resistance processes is a broad area of research that aims to increase our understanding of the nature of each tumor and the biologic features that make it resistant, as well as to facilitate the design of new therapies directed against these tumors. In this second article, having covered the topical treatments of nonmelanoma skin cancer, we review resistance to other nonsurgical treatments, such as monoclonal antibodies against basal and squamous cell carcinomas, intralesional chemotherapy, photodynamic therapy, and radiotherapy.

KEYWORDS:

Cetuximab; Cáncer cutáneo; Drug resistance; Methotrexate; Metotrexato; Photodynamic therapy; Radioterapia; Radiotherapy; Resistencia a fármacos; Skin cancer; Terapia fotodinámica; Vismodegib

PMID:
27436804
DOI:
10.1016/j.ad.2016.04.020
[Indexed for MEDLINE]

Publication type, MeSH terms, Substances

Publication type

MeSH terms

Substances

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center